Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
– Presented Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition – – Two Additional Phase 3 Readouts of Mitapivat Expected in 2024, with a Total of Four Phase 3 Readouts by the End of 2025 – – U.S. PYRUKYND ® (mitapivat) Net Revenue of $7.1 Million in Q4; Cash, Cash Equivalents and Marketable Securities of $806.4 Million as of December 31, 2023 – CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023. “The past 12 months have been remarkable for Agios. We reported positive data across our industry-leading pipeline of PK activators, including Phase 3 data in non-transfusion-dependent thalassemia, Phase 2 data in sickle cell disease and clinical proof-of-concept in
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024GlobeNewswire
- Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $29.00 to $33.00. They now have a "neutral" rating on the stock.MarketBeat
- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
AGIO
Earnings
- 5/2/24 - Beat
AGIO
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/26/24 - Form ARS
- AGIO's page on the SEC website